Monopar Therapeutics Earnings Per Share Disclosure
Note 8 – Loss per Share
Basic and diluted net loss per common share was calculated as follows:
| (in thousands, except for net loss per share) | Years Ended December 31, | |||||||
| 2024 | 2023 | |||||||
| Numerator: | ||||||||
| Net loss | $ | (15,586 | ) | $ | (8,402 | ) | ||
| Denominator: | ||||||||
| Weighted-average common shares outstanding | 3,771 | 2,765 | ||||||
| Weighted pre-funded warrants outstanding | 19 | - | ||||||
| Weighted-average common shares outstanding, basic and diluted | 3,790 | 2,765 | ||||||
| Net loss per common share, basic and diluted | $ | (4.11 | ) | $ | (3.04 | ) | ||
| Anti-dilutive potential common stock equivalents excluded from the calculation of net loss per share | ||||||||
| Stock options to purchase common stock | 429 | 422 | ||||||
| Unvested restricted stock units | 41 | 84 | ||||||
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.